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ABSTRACT 
Inflammation is associated with Alzheimer’s disease (AD), a neurodegenerative disorder with 
no cure up to date. Ample evidence from studies within various disciplines support that 
inflammation plays a role in AD. Resolution of inflammation is the end stage of 
inflammation, where the detrimental effects of inflammation are terminated and tissue 
healing is initiated. Cutting-edge research has demonstrated that resolution of inflammation is 
controlled by specialized pro-resolving lipid mediators (SPMs). There is emerging evidence 
for a role of SPMs in various diseases associated with inflammation. One of the SPMs, 
neuroprotectin D1 (NPD1) was the first to be found in reduced levels in the brain of AD 
patients. The aims of this thesis were to investigate the resolution status in AD, the 
mechanisms therein, and the therapeutic potential. 
In Paper I, we aimed to answer the fundamental question, whether and how the resolution 
pathway is altered in AD patients. To this end, we analysed cerebrospinal fluid (CSF) and 
postmortem samples from AD and non-AD patients. We found that in the CSF and 
hippocampus of AD patients, the levels of one of the SPMs, lipoxin A4, LXA4 were lower 
than that in non-AD groups. This was further confirmed by analysis of a smaller number of 
hippocampal samples with liquid chromatography - tandem mass spectrometry (LC-MS-MS) 
technique, which also revealed that another SPM, maresin 1 (MaR1) was reduced in AD 
hippocampus. Furthermore, the CSF levels of LXA4, as well as resolvin D1 (RvD1), were 
positively correlated to mini mental statement examination (MMSE) scores. The cellular 
distribution of two SPM receptors, LXA4 receptor/formyl peptide receptor 2 (ALX/FPR2) 
and chemerin receptor 23 (ChemR23) were also described in the human brain. We then 
investigated if the abnormal resolution may play a role in the pathogenesis of AD. For this 
purpose, in Paper II, we used a senescence-accelerated mouse model, SAMP8 mice, to study 
the balance between inflammation and resolution during an abnormal aging progress, since 
the primary risk of AD is aging. We found that inflammation in SAMP8 mice increased with 
age, and was higher than that in age-matched control mice. However, the resolution markers 
LXA4 and RvD1 remained unchanged upon age in SAMP8 mice, or equal to the levels in 
control mice. Thus, SAMP8 mice appeared to have an unresponsive resolution during the 
abnormal aging. We also found that enzymes involved in the synthesis of SPMs were 
abnormally regulated during aging in SAMP8 mice, and that this was related to amyloid β 
(Aβ) and tau pathology. In Paper III, we analysed materials from a double-blind, 
randomized, placebo-controlled clinical trial, where n-3 fatty acids or placebo were orally 
supplemented to AD patients for 6 months. Peripheral blood mononuclear cells (PBMCs) 
were obtained before and after the trial, and incubated with Aβ ex vivo. We found that there 
was reduced production of LXA4 and RvD1 by the Aβ-exposed PBMCs in the placebo group, 
and that n-3 fatty acid supplementation prevented this reduction. There was a positive 
correlation between altered levels of plasma transthyretin, and the SPMs released from the 
PBMCs. Finally, in Paper IV, we investigated the therapeutic potential of a resolution-
stimulating strategy. Using LC-MS-MS technique, we were able to study a broad range of 
lipid mediators, and found that MaR1 is also reduced in the entorhinal cortex of AD patients. 
MaR1, as well as LXA4, RvD1, and NPD1 showed direct neuroprotective effects against 
staurosporine-induced cell death in vitro, and MaR1 specifically exerted phenotype-
modulation effects on human microglial cells, and promoted the phagocytosis of Aβ. 
In conclusion, we have demonstrated that the resolution pathway is altered in AD, and has a 
relationship with disease development and pathology. Novel therapeutic strategies based on 
stimulating resolution should be further investigated. 
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1 INTRODUCTION 
The human brain is perhaps the most amazing art of nature. It gives us the abilities to 
recognize the world and the mind, to memorize the tears and the smiles, to reform the world 
and remould the thought. However, these abilities wither as the brain becomes dysfunctional. 
1.1 ALZHEIMER’S DISEASE 
1.1.1 General aspects 
Alzheimer’s disease (AD) is a neurodegenerative disorder that causes the most common type 
of dementia. The history of AD dates back to more than 100 years ago, when the German 
psychiatrist and pathologist Alois Alzheimer first described the pathologies of brain atrophy, 
senile plaques and neurofibrillary tangles in the brain of a demented woman in 1906 [1]. In 
recent years, the ‘golden standard’ for determination of AD based on these two hallmarks in 
the post-mortem brain examination became considered as just one of several diagnostic tools, 
which include new developing guidelines based on clinical symptoms, imaging and 
laboratory examinations in favour of clinical practice [2,3].  
There are about 35 million people suffering from dementia, among which more than half may 
be of the AD type, and the number is expected to grow to 150 million. Epidemiologically, 
AD can be divided into two groups, the sporadic and familial, of which the latter is clearly 
associated with strong familial heredity. Sporadic AD accounts for the major proportion 
(about 95%) of AD cases, and the familial form thus only represents a small minority of the 
afflicted population [4].  
The clinical symptoms of AD are characterized by progressive loss of memory and cognition, 
believed to be associated with neuronal damage in the brain. AD can lead to inability with 
working and everyday life. In the late stage, the AD patient may need to be hospitalized due 
to difficulties with basic daily living activities, such as eating and bathing. The lifespan after 
the diagnosis of AD is usually less than 10 years [5,6]. AD does not only results in suffering 
for the patient, but also becomes a serious burden for the patient’s family and the social 
healthcare system. 
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1.1.2 The evidence of inflammation in AD - Observations 
In the 1980s, about 80 years after Dr. Alzheimer’s description of AD, the presence of 
inflammatory reactions in the postmortem brain of AD patients was discovered [7-10]. 
Immunoglobulins and complement factors, representing immune responses, were found to be 
associated with senile plaques in the AD brain [7]. Later on, microglia, the cells representing 
the innate immune system in the brain, were found to be more reactive in the AD brain [8,9], 
and levels of interleukin (IL) -1, a classical inflammatory cytokine, found to be elevated [10]. 
The presence of abnormal inflammation in the AD brain has since been confirmed by other 
studies [11-16].  
Signs of an inflammatory process in AD were not found only in the brain, but also in body 
fluids. In the cerebrospinal fluid (CSF) of AD patients, higher levels of pro-inflammatory 
cytokines such as IL-6, IL-1β, tumor necrosis factor-α (TNF-α), and acute phase protein α-1-
antichymotrypsin levels were reported, although some reports of decreased or unchanged 
levels have also been published (reviewed in [17]). Similar findings have been reported for 
the levels in serum/plasma samples (reviewed in [17]). 
Besides these laboratory examinations on clinical materials from AD patients, strong support 
of elevated inflammation is also available from the live examination by clinical imaging 
techniques. Using positron emission tomography (PET) technique, it was possible to detect 
increased activation of microglia cells in the brain of living AD patients [18-20]. Activated 
microglia were found to be more numerous also in the brain of mild cognitive impairment 
(MCI) patients [21], who are believed to be at high convert rate to AD. The levels of 
activated microglia detected by this method did not differ between MCI and AD patients 
[21], suggesting an early role of inflammation in the development of AD.  
Evidence of an early role for inflammation in the development of AD is also provided by 
epidemiological studies. In 1989, the first report was published regarding a lower incidence 
of AD in patients with rheumatoid arthritis [22], which is an autoimmune disease mainly 
affecting the joints and other peripheral organs. Patients with rheumatoid arthritis are usually 
prescribed with anti-inflammatory drugs, and hence, in a report from 1990, McGeer and co-
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workers suggested that the use of anti-inflammatory drugs in these patients may be a 
protective factor against development of AD [23]. Later on, large cohort epidemiological 
studies on the association between use of anti-inflammatory drugs and AD have been 
published. The Rotterdam study, a longitudinal study following more than 7000 subjects, 
reported a relative risk for AD of 0.38 in users of non-steroidal anti-inflammatory drugs 
(NSAIDs), compared to those not using NSAIDs [24]. In the follow-up study, it was reported 
that 24 months medication with NSAIDs, or longer, was associated with a relative risk for 
AD of 0.20, compared to 0.83 when using NSAIDs for more than 1 month but less than 24 
months [25].  
Evidence for the involvement of inflammation in AD was also obtained from the field of 
genetics. Genome-wide association studies (GWAS) have identified polymorphisms of genes 
related to immune responses, such as CR1/CD35 and CD33, with strong association with AD 
(reviewed in [26]). A recent report by Raj T et al (2014) also indicated that expression 
quantitative trait loci for risk gene variants of AD were over-represented in monocytes, a 
leukocyte from the myeloid compartment, also the origin of brain microglia, indicating a vital 
role of the innate immune system in genetic risk factors for AD [27]. 
1.1.3 The role of inflammation in AD - Ideas 
With the observation of inflammation in AD, it is of importance to consider its role, 
especially from an aetiological perspective, and below follows hypotheses regarding possible 
mechanisms by which inflammation may play a critical role in AD pathogenesis. 
1.1.3.1 Inflammation and amyloid-β 
 Certain gene mutations have been identified to result in heredity of AD. These mutations 
include the genes for amyloid-β precursor protein (AβPP), and presenilin (PS) 1 and 2 
proteins [4]. As indicated above, familial AD (FAD) only accounts for a minor proportion of 
all AD cases, and the proportion of cases with these three mutations is even less, representing 
approximately 55-70% of known FAD cases [4]. Thus, the aetiology of the majority of AD 
cases, especially the sporadic type, is still largely unknown.  
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Almost all the mutations found on the three genes in FAD are related to the increased 
production of amyloid β (Aβ) [28], the principle component of senile plaques found in the 
postmortem AD brain. Based on the genetic findings from the FAD, the Aβ cascade 
hypothesis was formulated, suggesting that abnormal Aβ accumulation is the central cause of 
AD type dementia [29,30]. Much research into AD is either directly focusing on Aβ, or 
indirectly related to it. Aβ, a peptide of about 36-43 amino acids, is produced from the AβPP-
presenilin complex through β- and γ-secretase [31].  
Inflammation has been proposed to be a critical intermediate for the disease development as 
part of the Aβ cascade hypothesis [31]. As described in the early reports on inflammation in 
the AD brain, the pro-inflammatory proteins and reactive microglial cells are associated with 
the senile plaques [7-10]. A common belief is that these inflammatory activities represent a 
response to the neurodegeneration in the brain. Furthermore, based on several in vitro studies 
(reviewed in [32]), the neuroinflammation is considered as a result of stimulation by the 
overabundant Aβ in the AD brain. Microglia, together with astrocytes, can be activated by Aβ 
through various sensors, including receptors such as toll-like receptors (TLRs) [33,34], 
receptor for advanced glycation endproducts (RAGE) [35-37], and formyl peptide receptor 2 
(FPR2) [36,38-41]. The activated microglia and astrocytes release pro-inflammatory factors 
such as TNF-α, IL-1β and reactive oxygen species (ROS), that are able to damage neurons 
[42-46] or blunt neurogenesis [47]. Furthermore, activated microglia may even destroy 
neurons directly through a phagocytosis-like process [48]. Inflammation may thus serve as a 
mediator for Aβ toxicity in the brain through the mechanisms described above.  
However, stimulation in the opposite direction must also be considered, i.e. that inflammation 
is a promoter of Aβ production, and thereby contributing to the neurodegenerative process. 
Disregarding the primary cause of inflammation, it is clear that inflammatory signals can 
regulate the production of Aβ [49]. For example, the pro-inflammatory cytokine IL-1β alone 
can enhance AβPP processing [50], and stimulation by interferon-γ (IFN-γ), IL-1β or TNF-α 
increased production of Aβ40 and Aβ42 [51,52]. The abnormally high Aβ levels can then 
further stimulate inflammation that mediates toxicity, or possibly exerts direct detrimental 
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effects to the neurons [53]. Thus, inflammation and Aβ could promote each other and form a 
vicious circle in the pathogenesis of AD [54].  
1.1.3.2 Inflammation and aging 
While the Aβ cascade hypothesis is being more and more questioned for various reasons, e.g. 
failures of clinical trials based on reducing Aβ [55], new hypotheses are being generated. 
Recently, Hunter S et al (2013) has proposed that AD, both familial and sporadic, could be 
due to senescence of the neurons in the brain, and that Aβ secretion is a response to 
senescence [56]. Indeed, aging is perhaps the most accepted risk factor for AD [57]. Most AD 
cases are diagnosed after the age of 65 [58]. The risk to develop AD doubles every 5 years 
after the age of 65, and after 85 years, the risk is more than 20 times higher than that at 65 of 
age [59].  
Signs of inflammation are present in the progress of aging. Serum levels of pro-inflammatory 
cytokines, such as IL-6 and TNF-α, are elevated with age [60,61]. Increased production of 
pro-inflammatory cytokines by blood mononuclear cells was found upon aging [62], and glial 
cells in the brain become more activated towards a pro-inflammatory status [63,64]. Some 
researchers concluded that aging is a process pushing inflammation, and pushed by 
inflammation, a phenomenon they termed ‘inflamm-aging’ [65,66]. According to this theory, 
the human body is continuously exposed to different types of stressors, such as radiation, 
antigenic, oxidative and thermal stimuli, that all can stimulate the immune system (especially 
the macrophages) during the entire life span. In this way, the inflammation level is growing 
chronically, and may impair pro-homeostatic mechanisms such as DNA repair systems and 
free radical scavenging. The balance between pro-inflammatory stressors and anti-
inflammatory rescuers is important in determining if the aging process is ‘successful’. For 
example, in healthy centenarians, the balance between pro-inflammatory factors, such as IL-1 
and IL-6, and anti-inflammatory factors, such as IL-10, plays a key role in their successful 
aging process [67,68]. As such, to balance the inflammatory and anti-inflammatory events 
could be an important strategy to achieve successful aging. On the other hand, age-related 
diseases, such as AD, could be associated with a disturbed balance between the two aspects. 
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1.1.3.3 Inflammation and ApoE 
Apolipoprotein E (ApoE) is a 34kDa lipoprotein abundant in both periphery and brain. There 
are 3 major isoforms of the APOE gene allele in human: E2, E3 and E4, of which E3 is the 
most common form (about 75%) and E2 is the least common (about 8%) [69]. APOE4, 
which appears in about 14% of the population, is associated with both familial and sporadic 
AD [70,71], and confers a dose-dependent increase in the risk for AD, and decreases the age 
of onset [72].  
The first described function of ApoE was the transport of lipids, but further studies have 
shown it to be involved in many other functions apart from lipid transport, including immune 
modulation [73]. Interestingly, the brain appears to be the second major source of ApoE 
protein after the liver [74]. Immunohistochemistry shows that staining for ApoE in the AD 
brain is associated with the senile plaques, and that it is increased in reactive astrocytes 
[75,76], indicating a link between ApoE, Aβ and inflammation. AD patients carrying the 
APOE4 allele were found to have an increase in activated microglia in the brain [77]. 
Transgenic mice with human APOE4 displayed higher levels of pro-inflammatory responses 
to lipopolysaccaride (LPS), both in the brain and periphery, compared with the mice carrying 
APOE3 isoform [78], in line with the findings in human that young and middle-aged APOE4 
carriers had higher plasma levels of pro-inflammatory cytokines, which may be associated 
with a risk for AD in late life [79]. In cellular studies, inflammatory reactions in microglia 
upon stimulation with secreted AβPP (sAPP-α) can be attenuated by the ApoE3 protein, but 
not by ApoE4 [80]. In a clinical study, the risk for AD was reduced by NSAIDs only in 
APOE4 carriers, and selective Aβ-lowering NSAIDs did not alter the risk-reducing effect 
compared to non-Aβ-lowering NSAIDs in these patients [81], indicating an effect of the anti-
inflammatory treatment that was independent of Aβ. 
1.1.3.4 Inflammation and tau 
In the debate about key players in AD pathogenesis, the neurofibrillary tangles consisting of 
hyperphosphorylated tau, cannot be forgotten, as it represents one of the two pathological 
hallmarks. While the normal physiological function of Aβ has not been well understood [82], 
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tau is known to act as a microtubule-binding protein that is essential for maintaining the 
stability of the neuronal cytoskeleton, and for normal cellular traffic [83]. Instead of binding 
to microtubules in a normal condition, highly phosphorylated tau (p-tau) that accumulates in 
a neuron forms paired helical filaments that are further turned into neurofibrillary tangles, 
disturbing the normal neuronal shape and function. While the Aβ cascade hypothesis is being 
challenged, interest in the importance of tau in for AD pathogenesis has been growing. As p-
tau levels seem independent of Aβ [84-86], and appear to change earlier than Aβ [87,88], 
researchers have proposed that drugs targeting tau would be preferential as disease-modifying 
drugs, while Aβ-targeting drugs may be more suitable for disease prevention [89].  
Also in connection to tau pathology, inflammation is a big part of the blue print. Similarly to 
Aβ, tau pathology can induce inflammation in the brain [90-92]. On the other hand, 
inflammation modulates tau. In the gene-manipulated mice that express human mutant tau 
genes, activation of microglia or chronic expression of pro-inflammatory cytokines, such as 
IL-1β, resulted in exaggerated p-tau pathology [93-95]. Interestingly, an immunosuppressant 
drug that can reduce microglial activation decreased the p-tau abnormalities [94]. Increased 
levels of total tau also represent a feature of the AD brain [96]. In vitro studies showed that 
pro-inflammatory cytokines, or conditioned medium from activated microglia, increased tau 
production, and this could be attenuated by anti-inflammatory drugs or IL-10 [97]. At the 
molecular level, tau homeostasis is based on the balance between phosphorylating and de-
phosphorylating activities. Studies on postmortem AD brains showed that tau 
phosphorylating kinases such as cyclin-dependent kinase 5 (cdk5) and p38/mitogen-activated 
protein kinase (p38/MAPK) are increased, and that tau de-phosphorylating phosphatases such 
as protein phosphatase 2A (PP2A), are reduced [98]. Inflammatory signals are known to 
enhance p-tau levels through activating the phosphorylation kinases [86,99]. 
1.1.4 Inflammation in the intervention of AD - Practices 
Based on the above findings, interventions of AD through an inflammation-focused strategy 
have been tested. The use of NSAIDs is the most relevant example. Inspired by the 
epidemiological findings, various types of NSAIDs have been tested for prevention or 
treatment effects in AD. In animal models of AD, NSAIDs have been shown to exert some 
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beneficial effects by reducing AD-related pathologies, and improving cognitive functions 
[100,101], but contrasting results that NSAIDs worsen AD-related pathologies have also been 
reported ([102,103] and reviewed in [104]). In clinical trials with NSAIDs on AD-patients, 
the results have been inconsistent, and almost no preventive effect, or reduction of AD 
symptoms could be concluded [105]. In contrast, the treatment with some NSAIDs could 
even increase the risk of AD [106,107], or worsen AD severity [108]. Moreover, many of the 
clinical trials with NSAIDs had to be terminated due to severe side effects, such as bleeding 
and cardiovascular diseases. The complicated results from clinical trials and epidemiological 
studies require further investigation of the mechanisms for NSAIDs’ activities in humans 
with different disease conditions. 
Another type of treatment strategy related to inflammation is the use of polyunsaturated fatty 
acids (PUFAs), especially the n-3 fatty acids (FAs). It is well accepted that intake of n-3 fatty 
acids, such as docosahexaenoic acid (DHA, 22C:6(n-3)) and eicosapentaenoic acid (EPA, 
20C:5(n-3)), benefits cardiovascular and other healthy aspects, many of which are attributed 
to anti-inflammatory effects [109]. Again, in animal studies, n-3 FA supplementation 
significantly reduced AD-related pathologies such as Aβ and p-tau [110], and improved 
learning and memory [111]. However, it becomes more complicated in clinical setting. The 
first large randomized, double-blind, placebo-controlled clinical trial was the OmegAD study 
[112]. In this study, 174 AD patients, of the 204 enrolled, concluded the study. The patients 
were randomized to orally take placebo or a supplement of 1.7 g DHA and 0.6 g EPA daily 
for the first 6 months, and in the following 6 months all patients were given this n-3 FA 
supplement. The overall conclusion from the OmegAD study is that there was no 
improvement in cognitive function in patients that received n-3 FA supplement. However, 
when analysing a sub-group of patients with MMSE > 27 at baseline, n-3 FA 
supplementation significantly reduced the MMSE decline rate. Within the same year, a study 
on supplementation with arachidonic acid (AA) and DHA showed improvement in cognitive 
function in MCI, but not in AD patients [113]. Similarly, a multi-centre study in which 225 
drug-naïve AD patients from five different countries were treated with placebo or a 
supplement with DHA (1.2 g) and EPA (0.3 g) daily for about 3 months, showed no 
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improvement in cognitive function, but in patients with MMSE of 24-26 at baseline, the n-3 
FA supplement improved a specific cognitive function, the delayed verbal recall [114]. The 
authors performed another multi-centre study, in which the inclusion criterion was MMSE ≥ 
20, and confirmed that the same supplementation could improve cognitive function [115]. 
Although the studies could not provide a significant effect in all AD patients, they showed 
some indication as to the potential for PUFA-based anti-inflammatory strategy against early 
stages of dementia. The complexity of the results stimulated further basic and clinical 
research, presented in the following sections. 
1.2 RESOLUTION OF INFLAMMATION 
1.2.1 Pro-resolving lipid mediators and the new concepts 
While NSAIDs are extrinsic tools made by pharmaceutical companies, resolution of 
inflammation, is the intrinsic system designed by nature with which inflammation is 
controlled and terminated. Acute inflammation is usually a defence reaction of the body to 
fight invading stimuli, such as pathogens and chemicals, or injury. In this sense, inflammation 
is a protective process. However, inflammation needs to be resolved, as the mechanisms by 
which harmful stimuli are destroyed and neutralized, are also be harmful to the tissue. 
Resolution of inflammation is not a novel concept. In general, during resolution of 
inflammation, 1) recruitment of inflammatory cells into the inflammation site is stopped, 
and/or the cells are switched to an anti-inflammatory phenotype, 2) non-phlogistic 
phagocytosis of stimuli and cell debris by macrophages is promoted, 3) pro-inflammatory 
signals are ceased and the pro-inflammatory mediator levels are down-regulated, 4) anti-
inflammatory signals and local cell/tissue survival signals are up-regulated, and 5) 
repair/regeneration of inflamed tissue is initiated [116]. Through such a process, the inflamed 
tissue/organ returns to homeostasis, and regains normal function. 
It was believed that the resolution of inflammation is a passive process following the removal 
or disappearance of inflammatory stimuli [117]. While some of the events in the resolution 
stage could be explained by the withdrawal of harmful stimuli, many questions at the cellular 
and molecular level remained unclear [117]. For example, in acute inflammation, it was 
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known that recruitment of macrophages into the inflammation site occurs a few hours later 
than the recruitment of neutrophils, but the initial mechanism of this sequential recruitment of 
inflammatory cells was not clear [117]. Questions regarding the intrinsic mechanism for 
pushing infiltrated granulocytes into apoptosis or to lymph nodes, and for the shift in 
macrophages to different phenotype spectra, were not clarified [117].  
Not until recent years has important information been provided on the mechanism of 
resolution, largely due to the serial discovery of specialized pro-resolving lipid mediators 
(SPMs) [118]. The SPMs are small molecular weight lipids derived from PUFAs, including 
AA, DHA and EPA. Upon the secretion of these mediators into to the inflamed tissue, 
resolution of inflammation is initiated and promotes the return of tissue homeostasis [118]. 
1.2.1.1 Lipoxins and programmed resolution 
Lipoxins (LXs) are the first identified SPMs. The discovery of LXs was in the early 1980s in 
the lab of Nobel Laureate, Professor Bengt Samuelsson, who discovered the AA metabolites 
prostaglandins (PGs) [119,120].  Similarly to PGs, LXs are also metabolites from AA. But 
unlike PG biosynthesis that requires cyclooxygenases (COXs) to catalyze AA, LXs were 
found to alternatively use lipoxygenases (LOXs) [120].  
There two major types of LXs, LXA4 and LXB4. The name ‘lipoxin’ is based on the key role 
of ‘lipoxygenases’ involved in their biosynthesis [119] (Figure 1). There are two major 
biological pathways for the synthesis of LXs. One of them involves the 15-LOXs (including 
15-LOX-1 and 2), that first oxygenize AA into 15S-hydroperoxy eicosatetraenoic acid (15S-
HpETE), and 5-LOX for convertion of 15S-HpETE to 5S,15S-diHpETE, which is finally 
converted into LXs (Figure 1). The other pathway is initiated by 5-LOX to catalyze AA to 
LTA4, which will be further converted by 12/15-LOX into LXs (Figure 1). Notably, the 5-
LOX initiated AA pathway is also able to produce leukotrienes. The epimer of LXA4, 15-epi-
LXA4, was found to be synthesized from AA through the aspirin-triggered (AT) COX-2 
pathway (Figure 1) [121].  
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Figure 1. Biosynthesis of lipoxins and other lipid mediators from AA. 
The biological functions of LXs, especially LXA4, were intensively studied soon after their 
discovery. LXA4 is perhaps the best studied SPM not only because of the early time of its 
discovery, but also truly for its biological significance. The first evidence of their pro-
resolving effects came from a leukotriene B4 (LTB4) induced skin inflammation model in the 
hamster cheek [122]. In this model, topically applied LXA4 dramatically reduced leukocyte 
infiltration and plasma leakage in the skin air pouch infused with LTB4 or PGE2. As the 
authors predicted, the pro-resolving role of LXs were robustly demonstrated afterwards. In 
various models in vivo and in vitro, LXA4 has been able to: cease inflammatory cell 
infiltration, attenuate inflammation-induced tissue damage, down-regulate pro-inflammatory 
cytokines and oxidative stressors (ROS), and promote phagocytosis and anti-inflammatory 
signals, such as IL-10 (reviewed in [116]). LXA4 and its epimer exert their biological actions 
through a G-protein coupled receptor, formyl peptide receptor 2 (ALX/FPR2) [123], for 
which also Aβ is a ligand. 
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A milestone finding for both LXA4 itself, and the idea of a programmed and active resolution 
process was established in 2001 [124]. In a model of acute skin inflammation induced by air 
pouch in mice, LTB4 appeared to be the first peak of increased pro-inflammatory mediators 
in the exudate, followed by PGE2. About 1-2 hours after the peak of these pro-inflammatory 
mediators, the levels of LXA4 were increased to a peak about 30-200 times higher than peaks 
of its AA siblings, LTB4 and PGE2. At the time of the LXA4 peak, the levels of LTB4, PGE2 
and neutrophil numbers were lower than their maximum levels, which were still much higher 
than baseline. This ‘class-switching’ of pro-inflammatory mediators to pro-resolving LXA4 
during an on-going inflammatory 
response strongly supported that 
resolution of inflammation is an active 
and intrinsic system that controls 
inflammatory response, and is 
programmed from the beginning of an 
inflammatory response (Figure 2) 
[125].  
1.2.1.2 Resolvins 
Inspired by the findings from LXs as pro-resolving metabolites from a PUFA, researchers 
identified resolvin (Rv) series from n-3 FAs, DHA and EPA, in the early 2000s, and named 
them according to their potent pro-resolving functions. The two series are RvDs, of which the 
precursor are from DHA, and RvEs that are derived from EPA [126].  
Resolvin D series 
In the biosynthesis of RvD1, 15-LOX-1 catalyses the conversion of DHA to 17S-HpDHA, 
which is oxygenized by 5-LOX and converted to RvD1 by further epoxidation and hydrolysis 
(Figure 3) [127]. Similar to LXs, there are also RvD epimers (AT-RvDs) derived in aspirin-
triggered COX-2 pathway (Figure 3) [127].  
There are six types of RvDs discovered in the human, i.e. RvD1-RvD6 [128], of which RvD1 
is the most studied so far. Similarly to LXA4, RvD1 exerts potent pro-resolving functions, 
Figure 2. Programmed resolution in inflammation 
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such as arresting granulocyte infiltration, down-regulating ROS and pro-inflammatory 
cytokines, and enhancing phagocytosis and expression of anti-inflammatory cytokines 
(reviewed in [116]). Of importance, RvD1 can modulate the expression of microRNAs 
(miRNAs), which play a vital role in controlling many aspects of cellular processes [129]. 
Moreover, RvD1 is able to modulate class-switching of the AA cascade, i.e. by inhibition of 
LTB4 production and enhancing LXA4 synthesis, through limiting the nuclear localization of 
5-LOX [130]. This provided the evidence that there may be a network regulation between 
SPMs. RvD1 was found to provide its biological functions through G-protein coupled 
receptor 32 (GPR32), as well as ALX/FPR2 [131], also serving as receptor for LXA4. 
Although LXA4 is also able to bind to GPR32, no specific functional outcome of the binding 
has been confirmed [131]. 
Figure 3. Biosynthesis of resolvins from DHA and EPA. 
Resolvin E series 
The synthesis of RvE1 can be initiated by either cytochrome P450 (CYP450), or aspirin-
modified COX-2 enzymes, converting EPA into 18R-HEPE, which is further metabolized by 
5-LOX (Figure 3) [132,133].  
Three RvEs have been discovered, i.e. RvE1, RvE2 and RvE3 [128], of which RvE1 has been 
well characterized. RvE1 has been found to reduce dendritic cell migration and their 
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production of IL-12, inhibit nuclear factor-κ B (NFκB), and promote granulocyte apoptosis 
and clearance (reviewed in [116]). Similarly to RvD1, RvE1 is able to increase the production 
of LXA4 [134]. The G-protein coupled receptor chemerin receptor 23 (ChemR23) was found 
to mediate RvE1 induced activities [135]. Moreover, RvE1 is also able to bind to, and acts as 
an antagonist of, the LTB4 receptor 1 (BLT1), which mediates pro-inflammatory LTB4 
functions [136].  
1.2.1.3 Neuroprotectins 
Neuroprotectins (NPDs, equal to the name protectins) are the SPMs first discovered in the 
nervous system, providing neuronal protection. Therefore, the name ‘neuroprotect’ was 
chosen, with ‘in’ for its inhibition of pro-apoptotic signals, and ‘D’ for being derived from 
DHA [137,138]. The brain and retina have very high levels of DHA that is essential for their 
development, maintenance and function, and the idea was formulated that specific functional 
derivatives from DHA may exist in the nervous system. In the mouse brain, and in a retinal 
pigment epithelium (RPE) cell line, NPD1 was discovered using liquid chromatography-
tandem mass spectrometry (LC-MS-MS) technique [137,138]. 
Figure 4. Biosynthesis of neuroprotectins from DHA. 
In the synthetic pathway of NPD1, 15-LOX-1 converts DHA to 17S-HpDHA, which is 
converted to NPD1 by further epoxidation and hydrolysis (Figure 4) [137,138]. Notably, 5-
LOX can also participate in this pathway, and convert 17S-HpDHA into 10S, 17S-diHDHA 
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(PDX), which are much less efficient than NPD1 (Figure 4) [137,139]. There is also an 
aspirin-triggered epimer for NPD1, AT-NPD1 (Figure 4) [140].   
NPD1 was early discovered to exert potent neuroprotective activities, such as in the mouse 
stroke-reperfusion model, by reduction of brain ischemia volume, and infiltration of 
granulocytes to the brain, and it was also shown to inhibit NFκB activation and COX-2 
expression [137]. In cultures of RPE cells, NPD1 was shown to protect from apoptosis 
induced by oxidative stress, through up-regulation of anti-apoptotic protein Bcl-2, and 
attenuated caspase-3 activation [138]. NPD1 has also been shown to inhibit COX-2 
expression and NFκB activation in IL-1β stimulated neuronal cell models [137,138]. 
1.2.1.4 Maresins 
Maresins (MaRs) are the SPMs found most 
recently, i.e. in 2009 [141]. They are 
derivatives from DHA, and were named 
maresins due to the original discovery in 
macrophages. 
Synthesis of MaR1 includes oxygenation of 
DHA by 12-LOX into 14S-HpDHA, followed 
by epoxidation and hydrolysis (Figure 5) [141]. 
5-LOX can alternatively convert 14S-HpDHA 
to 7S, 14S-diHDHA (Figure 5), which 
possesses some, but weaker pro-resolving 
function than MaR1 [139,141].                Figure 5. Biosynthesis of MaR1 from DHA 
MaR1 was identified first, and MaR2 was discovered this year [142]. MaR1 is able to reduce 
granulocyte infiltration to an extent comparable to NPD1 and RvE1 [141]. As a product from 
macrophages, MaR1 shifts macrophages from a pro-inflammatory phenotype (M1) to an anti-
inflammatory/phagocytic phenotype (M2), and inhibits LTA4 hydrolase [143], which is 
involved in the production of LTB4 from AA. Interestingly, MaR1, together with RvE1, was 
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found to promote tissue regeneration in surgically injured worms [144], providing evidence 
of pro-regenerative function of SPMs. 
1.2.2 Resolution of inflammation in health and diseases 
1.2.2.1 Roles of SPMs in normal physiology 
As SPMs were discovered in animal models and cellular studies, it is of importance to 
confirm their presence in humans. It has been established that almost all the SPMs could be 
identified in healthy human serum [128], confirming the significance of SPMs in human 
health.  
Milk, the first food for a human being, contains high levels of SPMs (in ng/ml) in the first 
month of lactation [145]. LXA4 (~ 15-22 ng/ml) appears to be the most prevalent among the 
SPMs found in milk, followed by RvD1 and RvE1. Moreover, the levels of these SPMs 
remained stable, regardless of the decreasing levels of their precursors AA and DHA. These 
findings indicate the potential importance of SPMs in the development of infants.  
The significance of SPMs in adults is also established. Physical exercise, especially resistance 
training, can induce acute inflammation that regulates muscle growth and maintenance. In 
this acute inflammation model, researchers have demonstrated the programmed resolution for 
the first time in humans [146]. In this study, serum samples were collected from healthy 
adults at 0-3 and 24 h after resistance exercises. Inflammatory mediators, such as 
thromboxane B2 (TxB2), LTB4 and PGE2, were increased in the acute phase, and 
accompanied by an enhanced production of SPMs.  
Thus, it is clear that SPMs are involved in the normal physiology of humans, and the roles of 
SPMs may be of importance in inflammation-related diseases. 
1.2.2.2 Roles of SPMs in peripheral diseases 
Asthma is an allergic disease of the airways, associated with chronic inflammation. We have 
recently shown that airway allergy can increase the phosphorylation of tau protein, and the 
expression of inflammatory genes, in the brain [147,148]. In patients with severe asthma, the 
levels of LXA4 [149,150] and NDP1 [151,152] are reduced. Administration of LXA4, RvD1, 
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RvE1 or NPD1 in animal models of asthma, reduced airway hyper-responsiveness, decreased 
pro-inflammatory mediator levels, and inhibited the infiltration of eosinophils into the lungs 
[134,151,153-155].  
Arthritis, such as osteoarthritis and rheumatoid arthritis, are chronic inflammatory diseases 
that affect the joints. As indicated above, long-term use of NSAIDs in patients with 
rheumatoid arthritis was associated with reduced prevalence of AD [23-25,156]. Treatment 
with SPMs in animal models of arthritis, including LXA4 [157] and RvD1 [158], could 
significantly relieve the symptoms of joint degeneration, probably via decreasing levels of 
TNF-α, IL-1β and LTB4. 
Diabetes mellitus (diabetes in short) is a metabolic disease that is caused by disturbance of 
insulin production or signalling, and obesity is a great risk factor for type 2 diabetes, the 
insulin resistant type [159]. Both diabetes and obesity are associated with inflammation, 
which serves as the link between the two diseases [160,161]. Notably, inflammation and 
insulin resistance are both associated with diabetes and AD, and type 2 diabetes doubles the 
risk to develop AD [162]. Pioglitazone, a drug that is commonly used to enhance insulin 
sensitivity in type 2 diabetes, was shown to increase plasma levels of LXA4 epimer in 
diabetic patients, indicating a potential link between LXA4 and the treatment effects of 
pioglitazone [163]. In addition, LXA4 treatment reduced age-related increase of IL-6, 
enhanced IL-10 production, as well as increased insulin sensitivity-related genes [164]. 
Furthermore, RvE1 was able to reduce LPS-induced inflammation, and apoptosis in human 
pancreatic islets induced by pro-inflammatory cytokines [165]. In diabetic wounds, the levels 
of NPD1 and RvD1 precursors were reduced, and treatment with NPD1 or RvD1 promoted 
wound healing [166,167]. In addition, RvD1 could increase insulin sensitivity in obese-
diabetic mice [168]. 
The emerging roles of SPMs and resolution in these AD-related peripheral diseases indicated 
potential links between resolution and AD. 
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1.2.2.3 Roles of SPMs in diseases of the nervous system 
Pain is a symptom that can be caused by many diseases, but it is always sensed through the 
nervous system in humans. The incidence of both pain and AD is increased with age, and 
pain may be undertreated in AD patients, due to inability to report pain [169]. LXA4, RvD1, 
RvE1, NPD1 and MaR1 were each shown to attenuate pain signalling through central and 
peripheral pathways in various inflammatory or traumatic pain models [144,170-173].  
Stroke, known as a cause of dementia, is a disease of the brain due to ischemic or 
haemorrhagic disturbance of the brain blood flow. Biosynthesis of NPD1 was found to be 
increased 1 h after ischemic stroke, and administration of NPD1 or AT-NPD1 reduced the 
brain infarct volume, improved neurological function, and promoted long-term repair 
mechanisms [137,140,174,175]. Similarly, treatment with LXA4, or its analogue, was also 
able to decrease the infarct volume and inflammatory mediators, ameliorate blood-brain 
barrier dysfunction and ischemia/reperfusion injury, and to enhance neurological recovery 
[176-181].  
1.3 RESOLUTION OF INFLAMMATION AND AD 
In AD, the proportions of AA and DHA in total FAs are decreased in different brain regions 
[182]. However, the consequential effects of these changes have not been clarified. As 
introduced above, a disturbance of the SPM production due to the decreased levels of their 
precursors is a reasonable result. The first light of resolution in AD was shed by NPD1 
studies in 2005. Lukiw et al. reported that in the cornu ammonis region 1 (CA1) of the 
hippocampus, the levels of NPD1 and DHA were significantly reduced in AD compared to 
age-matched controls [52]. The authors also showed that NPD1 provided neuroprotection 
against Aβ42 induced cytotoxicity in neuron-glia co-cultures, through an up-regulation of anti-
apoptotic gene expression and down-regulation of pro-apoptotic gene expression [52]. Later 
on, Medeiros et al. demonstrated that AT-LXA4 treatment reduced AD-like pathologies, 
improved synaptic density and modulated glial cell functions, in AD transgenic mice 
[183,184]. Thus, considering the inflammation in AD, and the roles of SPMs in resolution of 
inflammation, we believe that a further insight into the resolution pathway in AD is needed to 
understand its possible role therein.  
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2 AIMS 
The main aim of this thesis is to provide an overall view of resolution of inflammation in 
AD, from the aspects of observations, ideas, practices and future ideas. 
The specific aims are: 
Paper I:  To characterize the status of resolution in the hippocampus and CSF of AD 
patients, and the possible relation to the stage of AD. 
Paper II:  To investigate how resolution is changed upon normal aging, and upon 
abnormal aging with AD-like symptoms and pathologies, using an animal 
model. 
Paper III:  To investigate if an anti-inflammatory treatment strategy, i.e. supplementation 
with n-3 fatty acids can influence the resolution of inflammation in AD 
patients, and how the influence may be related to other treatment effects. 
Paper IV:  To further characterize the profile of SPMs in entorhinal cortex of AD patients, 
and explore whether stimulation with SPMs may have functional effects in 
neuronal and glial cell models, in order to provide evidence for future 
development of therapeutic strategies based on SPMs. 
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3 MATERIALS AND METHODS 
3.1 HUMAN, ANIMAL AND CELL MODELS 
3.1.1 Human postmortem brain samples 
The central pathological changes of AD are in the brain, and thus the AD brain is of the most 
interest when investigating a new factor/pathway in AD. Obtaining biopsies from a human 
brain is of obvious difficulty, and thus autopsy (postmortem) brain tissue becomes a valuable 
source. The age at death and the postmortem interval (PMI) are two important factors that 
may influence the analysis of postmortem samples, and need to be matched between the 
experimental groups. Postmortem human brain samples in Paper I and IV were obtained 
from the Brain Bank at Karolinska Institutet. In Paper I, hippocampal samples from 10 AD 
patients and 10 non-AD subjects without significant neurological disorders (control subjects) 
were used. The age at death and the postmortem interval (PMI) did not differ between the AD 
and non-AD group. In Paper IV, samples of entorhinal cortex from 7 AD patients and 7 
control subjects were analysed. No difference was found regarding age and PMI (PMI from 
one subject was not available) between two groups. Severity of pathology is another factor to 
be considered when collecting postmortem samples. In both studies, all the AD brains were 
evaluated as Braak stage V-VI (except one case was stage III-IV), and there were no 
significant pathological changes in the control brains.  
3.1.2 Human CSF samples 
CSF is the body fluid secreted by the choroid plexus. It covers the entire brain and spinal 
cord, and actively interacts with interstitial fluid of the brain parenchyma. Because changes of 
CSF components can reflect the changes in the brain and can be ‘biopsied’ through lumbar 
puncture, CSF is a commonly used sample for neurological examinations. In Paper I, CSF 
samples from 15 AD patients, 20 MCI patients, and 21 individuals with subjective cognitive 
impairment (SCI), were obtained from the Memory Unit of Geriatric Clinic at Karolinska 
University Hospital, Huddinge. The age of the AD group is 68 ± 10 years, and that of MCI 
group is 66 ± 10 years (mean ± SD). The age of the SCI group (57 ± 5 years) was younger 
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than the AD and MCI group. All of these 56 patients underwent routine clinical examinations 
including MMSE test and measurement of CSF p-tau (threonine 181). 
3.1.3 The OmegAD study and blood mononuclear cells 
Paper III is a second outcome sub-study from the OmegAD study, which is a double-blind, 
placebo-controlled, randomized clinical trial. The trial enrolled 204 AD patients from the 
beginning, and 174 patients completed the trial. Patients were randomized into two groups for 
the first 6 months, the n-3 FA supplement group receiving encapsulated 1.7 g DHA and 0.6 g 
EPA (EPAX1050TG; Pronova Biocare A/S, Lysaker, Norway) daily, and the placebo group 
receiving 1 g corn oil capsules (containing 0.6 g linoleic acids) daily. Vitamin E, an anti-
oxidant, was also equally supplemented with the capsules to all the patients. After 6 months, 
all the patients received the n-3 FA supplementation for another 6 months. The primary 
outcomes have been reported previously [112]. A sub-population of 17 patients was included 
in Paper III. Two of the patients dropped out during the first 6 months trial, and finally 15 
patients concluded the study, of which 8 patients (3 females), aged 72.5 ± 8.2 years (mean ± 
SD) received the n-3 FA supplementation, and 7 patients (2 females), aged 70.4 ± 6.6 years 
(mean ± SD) received placebo. There was no difference in age, MMSE score, plasma DHA 
and EPA levels, blood pressure, body weight or intake of aspirin, between the groups. Blood 
samples were taken before and after the first 6 months trial.  
Blood mononuclear cells, including monocytes, T-lymphocytes, B-lymphocytes and natural 
killer (NK) cells, represent the immune system in the peripheral blood. While not possible to 
directly analyse brain cells from living patients, PBMCs were chosen as an ex vivo model to 
investigate the effects of the clinical trial on the inflammatory response to a stimulus. 
Moreover, PBMCs have been found to participate in the AD-related changes in the brain 
[185-190]. The venous blood samples obtained from the patients were treated with EDTA to 
prevent coagulation, and the PBMCs containing about 15% monocytes and 85% lymphocytes 
were isolated by gradient centrifugation (Nycomed Pharma, Oslo, Norway).  
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3.1.4 SAMP8 and SAMR1 mice 
The senescence-accelerated mouse prone 8 (SAMP8) is a non-transgenic mouse strain with 
an abnormal aging progress, which displays AD-like pathologies and symptoms (reviewed in 
[191]). The senescence-accelerated mouse resistant 1 (SAMR1) is a mouse strain with a 
relatively normal aging progress, which has no AD-like changes. SAMP8 and SAMR1 mice 
were generated by phenotype difference from the AKR/J mouse strain [192,193]. SAMP8 is 
mainly considered as a model for aging, because of the accelerated aging process, and the 
multiple organ abnormalities [194]. However, it is also widely used as an AD-related model, 
as the SAMP8 mice display AD-like pathologies and symptoms, such as increased Aβ and p-
tau, neuronal loss, and impaired spatial memory [195].  
In Paper II, male SAMP8 and SAMR1 mice of 2 and 9 months age were used for the 
studies. For biochemical assays, the mice were injected intraperitoneally (i.p.) with a lethal 
dose of pentobarbital sodium. The brain was immediately removed, and the hippocampus 
was dissected out bilaterally and kept at -80°C until further processing. For morphological 
analysis, the mice were anesthetized with pentobarbital sodium i.p., and perfused with 4% 
paraformaldehyde via the left ventricle. The perfused brains were then kept in 4% 
paraformaldehyde at 4°C overnight, and transferred to 10% sucrose until sectioned. 
3.1.5 SH-SY5Y neuroblastoma cell line 
SH-SY5Y (Paper IV) is a human neuronal cell line derived from bone marrow autopsy of an 
adrenergic neuroblastoma patient. The undifferentiated SH-SY5Y cells are neuroblast-like 
and highly proliferative, and can be differentiated by various agents. Sequential culture with 
retinoic acid (RA) and brain derived neurotrophic factor (BDNF) differentiates SH-SY5Y 
cells into a cholinergic neuron-like cell population, which also possesses some dopaminergic 
properties [196]. The cells were cultured in DMEM/F12 medium, supplemented with 10% 
heat-inactivated fetal calf serum (FCS) at 37°C in humidified air containing 5% CO2. The 
cultured cells were differentiated with 10 µM RA for 5 days. The differentiated cells were 
harvested with enzyme-free dissociation buffer, and seeded at 20 000 cells/well in a 48-well 
plate coated with Matrigel. The cells were allowed to attach to the plate for one day, and then 
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the culture medium was replaced with serum-free medium containing 25 ng/ml BDNF. 
Experiments were performed 5 days thereafter. 
3.1.6 CHME3 microglia cell line  
CHME3 is a human microglial cell line derived from human embryonic tissue via 
transfection with the SV40 large T antigen, which makes the microglia immortal and 
proliferate spontaneously [197]. In Paper IV, CHME3 was obtained as a kind gift from 
Professor Marc Tardieu (Université Paris South). The cells were cultured in DMEM/high 
glucose medium supplemented with GlutaMaxII (Life Technologies, Stockholm, Sweden) 
and 10% FCS. The culture medium was changed twice per week. The cells were split at 80% 
confluence, and seeded into 6-well plates for experiments and propagation. 
3.2 EXPERIMENTS EX VIVO AND IN VITRO  
3.2.1 Release of SPMs from PBMCs ex vivo 
In Paper III, the cultured PBMCs were incubated with Aβ40. Aβ40 is a more abundant form 
in plasma than other Aβ peptides [198], and it has been shown that Aβ40 can reduce the 
production of IL-10 by PBMCs [199]. Aβ40 peptide (Bachem, Heidelberg, Germany) was 
dissolved in dimethyl sulfoxide (DMSO), and added to the cultures at a final concentration of 
7 µM, as this concentration of Aβ40 was shown to be more absorbed by cellular lipid 
membrane [200], without inducing significant cell death in vitro [201]. Aβ40 has been shown 
to increase lipid peroxidation [202], which may be linked to SPM biosynthesis. DMSO (1%) 
was used as vehicle. After 22 h incubation at 37°C with 5% CO2, the cell cultures were 
centrifuged, and the supernatants were collected for further analysis of lipid mediators. 
3.2.2 Effects of SPMs on the survival of SH-SY5Y cells 
In Paper IV, to analyse the effect of SPMs on neuronal survival, the differentiated SH-SY5Y 
cells were treated with 100 nM staurosporine (STS), a protein kinase inhibitor widely used 
for inducing neuronal apoptosis [203].  The SPMs MaR1, LXA4, RvD1 and NPD1, at a range 
of 0 - 0.5 µM, were added to the cultures immediately prior to addition of STS. The treatment 
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with SPMs was repeated by addition to the cultures at 6 and 24 h, and viability and cell death 
were analysed at 48 h. The effects of SPMs alone in the absence of STS were also analysed. 
3.2.3 Effects of SPMs on phagocytosis of Aβ42 by CHME3 cells 
In Paper IV, to assess the effects of SPMs on phagocytosis of Aβ42, CHME3 cells (100,000 
cells/well) were seeded into 6-well plates, and incubated with 1 µg/ml HiLight488-
conjugated Aβ42 (Anaspec, Fremont, USA), together with a range of concentrations (0 - 100 
nM) of SPMs for 1 and 6 h. Phagocytosis of Aβ42 was analysed by flow-cytometry. 
3.2.4 Effects of MaR1 on microglia phenotype markers 
In Paper IV, to analyse the effects of MaR1 on microglial phenotype, the CHME3 cells were 
seeded into 6-well plates and incubated with 0 - 1 µM MaR1 for 6 h, at which time point the 
cells were harvested for flow-cytometry analysis. 
3.3 ANALYTICAL TECHNIQUES 
3.3.1 Enzyme immunoassay (EIA) 
Enzyme immunoassays (EIAs) were used through Paper I-III. The assays included LXA4 
EIA kit (Oxford Biochemical Research, MI, USA), RvD1 EIA kit and LTB4 EIA kit (both 
from Cayman Chemical, MI, USA). These EIA assays are based on competition between the 
analyte in the sample and an enzyme-conjugated analyte, to bind to the limited amount of 
antibodies attached to the plate well. Thus, the amount of analyte in the sample is inversely 
correlated to the optical signals detected. Compared to LC-MS-MS, the advantage of using 
EIA assays is that many samples can be assessed simultaneously in one plate, making the 
comparison between the samples faster and less variable. One the other hand, the EIA assays 
may be less specific than LC-MS-MS, and provide less analyte information.  
For lipid extraction in CSF and culture medium, samples were diluted and acidified to pH 
3.5. The acidified samples were then added at 0.5 ml/min onto a C18 column, preconditioned 
with methanol and water. The C18 column was then washed by water and hexane. Lipids 
were eluted by methyl formate, and dried by nitrogen gas. The dried samples were 
resuspended in extraction buffer supplied by the LXA4 EIA kit, for further analysis. Tissues 
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were homogenized and centrifuged. The supernatants were collected and processed as 
described above. All of the analyses were performed according to the manufacturers’ 
instructions. 
3.3.2 LC-MS-MS 
LC-MS-MS method was used in Paper I and IV for analysis of lipid mediators (LMs) in 
postmortem tissues from the hippocampus and entorhinal cortex. Compared to EIA assays, 
LC-MS-MS has higher specificity and broader range of detection (several types of analytes 
can be assessed simultaneously in one sample). However, LC-MS-MS costs much more time 
than EIA assays, and the accuracy and variation between different assessments are much 
dependent on the equipment, experimental settings, and the strategy of data analysis [204].  
For lipid extraction, tissues were gently dispersed by a glass dounce. Internal deuterium-
labelled standards in ice-cold methanol were added into each sample, in order to facilitate 
quantification and sample recovery. The samples were kept at -20°C for 45 min for protein 
precipitation, and were then centrifuged (4°C for 10 min). Supernatants were collected and 
brought to less than 1 ml of methanol content by nitrogen gas. An automated extraction 
system (RapidTrace, Biotage, NC, USA) was used to extract the samples as in [128,205].  
The LC-MS-MS system included a LC-20AD HPLC and a SIL-20AC auto-injector 
(Shimadzu, Kyoto, Japan), paired with a QTrap 6500 (ABSciex, CA, USA). LMs were eluted 
through an Eclipse Plus C18 column with a flow rate of 0.4 ml/min. The QTrap 6500 was 
operated in negative ionization mode. Scheduled multiple reaction monitoring (MRM) with a 
90 s window was coupled with information-dependent acquisition (IDA) and an enhanced 
product ion scan (EPI) [128,205]. Each LM parameter was optimized individually, and was 
monitored by recently published criteria [128,205], including matching retention time to 
synthetic and authentic materials, and employing at least six diagnostic ions for each LM.  
3.3.3 Multiplex cytokine assay 
In Paper I, a human inflammatory cytokine assay (MesoScale Discovery, MD, USA) was 
used for analysis of the cytokine levels in the hippocampus. This multiplex assay is in a 
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sandwich immunoassay format similar to traditional enzyme-linked immunosorbent assay 
(ELISA), but can detect multiple analytes in one single assay, as the plate is pre-coated with 
several types of antibodies on separated spots in each well. Compared to traditional ELISAs 
that can only analyse one marker in one experiment, the multiplex assay makes it possible to 
assess more markers simultaneously, and use less samples. This advantage is valuable for 
optimized usage of samples that are in a limited quantity, e.g. human brain samples.  
The cytokines/chemokine that were analysed include IFN-γ, IL-1β, IL-12p70, IL-6, IL-8, IL-
10 and TNF-α. Hippocampal tissues were homogenized by sonication. The homogenates 
were centrifuged at 20 000 x g for 15 min at 4°C, and the supernatants were collected for 
analysis. The MesoScale assay was performed according to the manufacturer’s instruction. 
3.3.4 Western blot 
Western blot is a semi-quantitative antibody-based method to assess levels of proteins that are 
separated by electrophoresis. In Paper I and II, human and mouse hippocampal samples 
were analysed by western blot. Tissues were homogenized as in section 3.3.3. Each sample 
containing 40 µg protein was boiled in Laemmli sample buffer at 95°C for 5min. The 
denatured proteins were separated by 10% SDS-polyacrylamide gel, and transferred to 
nitrocellulose membranes. The membranes were blocked in 5% non-fat milk for 30 min at 
room temperature (RT), and then incubated at 4°C overnight with primary antibodies. After 
washing, the membranes were incubated with horseradish peroxidase (HRP)-conjugated 
secondary antibodies for 2 h at RT. Finally, the membranes were developed with 
electrochemiluminescence reagent, followed by detection with a CCD camera (Fuji Film, 
Tokyo, Japan). Analysis of the blots was carried out using Multi Gauge software (Fuji Film, 
Tokyo, Japan). All the blots were normalized to β-actin as the housekeeping protein.  
3.3.5 Immunohistochemistry 
Immunohistochemistry is a useful technique to study both morphological and quantitative 
aspects of a marker in tissue sections. So far, the distribution of resolution pathway markers 
in the brain is only partially described, and it was of interest to further analyse these in the 
human and mouse brain tissues. Moreover, when a marker is expressed by different types of 
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cells in the tissue, the immunohistochemical technique enables assessment of the expression 
in all cell types simultaneously, whereas the western blot technique will only analyse the total 
levels from all a mixture of cells.   
3.3.5.1 Paraffin-embedded human brain tissue 
Paraffin embedding allows long-term storage of samples without temperature control, and 
preserves better the morphological structures than frozen tissue. This is advantage that is 
taken into consideration when processing human postmortem samples, which are limited in 
source and quantity. However, paraffin embedding may influence the antigenicity. If a certain 
marker is undetectable, an antigen retrieval method can be applied. Another problem in the 
case of postmortem brain tissue from aged individuals, is the autofluorescence due to 
lipofuscin, which makes it difficult to distinguish the specific antibody staining from 
unspecific autofluorescence. Thus, peroxidase- or alkaline phosphatase (AP)-based 
immunohistochemical methods are commonly used for postmortem human brain tissue. 
The paraffin-embedded tissue sections (Paper I) were deparaffinized, and endogenous 
peroxidase was blocked with 1% H2O2. After subsequent blocking with 5% serum at RT for 
30 min, the sections were incubated overnight at 4°C with primary antibodies. After washing, 
the sections were incubated with biotin-conjugated secondary antibodies for 1.5 h at RT, 
followed by incubation with streptavidin-HRP complex for 30 min at RT. The staining was 
developed with 1 mg/ml diaminobenzidine (DAB) solution in the presence of 0.02% H2O2, 
and counterstained with cresyl violet.  
Double immunostaining on paraffin-embedded tissue (Paper I) was performed as described 
above, except for an additional step of heat-induced antigen retrieval for the human leukocyte 
antigen type DR (HLA-DR) staining. The sections were incubated with BLOXALL (Vector 
Laboratories, CA, USA) to block endogenous peroxidase and AP. After serum blocking, the 
sections were incubated with primary antibodies including ALX/FPR2, ChemR23 and 15-
LOX-2, mixed with antibodies to the astrocyte marker glial fibrillary acid protein (GFAP), or 
the microglia marker HLA-DR. After washing, a mixture of biotin- or AP- conjugated 
secondary antibodies was applied for 1.5 h at RT, followed by streptavidin-HRP complex 
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incubation for 30 min at RT. Peroxidase-based staining was developed with Nova Red, and 
AP-based staining was developed with Vector Blue (Vector Laboratories, CA, USA). 
3.3.5.2 Frozen mouse brain tissue 
Immunofluorescence is based on fluorophore-conjugated antibodies, and can be used in 
confocal laser microscopy or two-photon excitation microscopy. The major limitation of 
immunofluorescence is photobleaching due to photochemical destruction. 
For immunofluorescent staining on frozen mouse tissues (Paper II), the sections were 
blocked with serum, and then incubated over night at 4°C with primary antibodies, followed 
by incubation with appropriate fluorophore-conjugated secondary antibodies for 1 hr at RT to 
visualize the staining.  
For double labelling on frozen mouse tissues (Paper II), sections were incubated with a 
mixture of: i) neuronal marker NeuN and one of the antibodies ALX/FPR2, ChemR23, L12-
LOX and 5-LOX, ii) GFAP or F4/80 mixed with 5-LOX, iii) L12-LOX and Aβ marker 4G8. 
A mixture of the appropriate secondary antibodies conjugated with red or green fluorophores 
was used to detect the staining. 
3.3.6 Lactate dehydrogenase (LDH) and resazurin assays 
LDH is a stable cytosolic enzyme that catalyses the conversion of NADH to NAD. When cell 
membrane permeability is disturbed due to cell death or injury, LDH will be released into 
extracellular space. Analysis of the enzymatic activity of LDH, released from damaged cells 
into the culture medium, serves as a measure of cell death. Resazurin is a blue chemical that 
can be converted into fluorescent resorufin by viable cells. Thus, the resazurin assay is used 
to assess cell viability in a cell culture. In Paper IV, we used both methods to assess the 
neuroprotective effects of SPMs on neuronal cells. 
Neuronal cell death was assessed by LDH assay. Cell culture medium was transferred to a 
96-well plate and incubated with LDH reagent for 30 min, and the absorbance were measured 
at 340 nm. The cells, which remain in the culture well, were assessed for cell viability by the 
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resazurin assay. The cells were incubated with resazurin salt at the final concentration of 
0.01% for 2 h at 37oC, and the fluorescence intensity was analysed at 590 nm.  
3.3.7 Flow-cytometry  
Flow-cytometry is a laser-based technique widely used in cellular studies. In Paper IV, the 
phagocytosis of Aβ and the analysis of microglial phenotype were assessed by flow-
cytometry. The fixed cells were washed and centrifuged at 400 x g for 10 min, and then 
resuspended with 1% bovine serum albumin (BSA). Cell suspensions were incubated for 45 
min on ice with fluorophore-conjugated antibodies. The cells were then washed and 
resuspended in 200 ml 1% BSA, and analysed in a FACSCalibur cytometer (Becton 
Dickinson, NJ, USA). The proportion of microglia positive for each cell surface marker was 
assessed by determining the percentage of cells showing a signal in the proper channel 
exceeding the signal of the isotype control.  
3.4 STATISTICS 
All statistical analyses were performed with SPSS software (IBM Corporation, NY, USA). 
Analysis of covariance (ANCOVA) was used in the analysis of EIA data on CSF samples in 
Paper I, using age as a covariance, because age is different among AD, MCI and SCI groups. 
The Mann-Whitney U-test or Student’s t-test was used to compare the group-wise differences 
in Paper I, III and IV, depending on whether the data were normally distributed. Two-way 
analysis of variance (ANOVA) using univariate general linear model (GLM) was used in 
Paper II, considering age and strain as two dependent variables. To compare the treatment 
effects of n-3 fatty acids and placebo, Wilcoxon signed rank test for analysis of paired 
samples was used in Paper III. The Kruskal-Wallis test followed by Mann-Whitney test was 
used to compare the effects of SPMs on neuronal and microglial cells in Paper IV. All 
through the studies, p < 0.05 was considered as statistical significant.  
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4 ETHICAL ASPECTS 
For Paper I and IV, the use of human CSF and postmortem brain samples has been 
approved by the ethical committee at Karolinska Institutet, the regional human ethics 
committee of the Stockholm County, and the Swedish Ministry of Health and Social Affairs. 
The ethical permit numbers are: 2011/680-31/1 for human CSF samples; Dnr 024/01 and 
2011/962-31/1 for human postmortem brain tissue. 
For Paper II, SAMP8 and SAMR1 mice were kept and sampled in University of Navarra, 
Spain. The use of SAM8 and SAMR1 mouse hippocampal tissue has been approved by the 
ethical committee at University of Navarra, in accordance with the laws of animal 
experiments, European Directive 86/609/EEC and the Spanish Real Decreto 1201/2005. The 
ethical permit number is: 004/08. 
For Paper III, the clinical trial of OmegAD study has been approved by the ethical 
committee at Karolinska Institutet, the regional human ethics committee of the Stockholm 
County, and the Swedish Ministry of Health and Social Affairs. The ethical permit number is 
Dnr 291/00. All the AD patients and their caregivers gave written consent before being 
enrolled in the clinical trial.  
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5 RESULTS AND DISCUSSION 
5.1 RESOLUTION OF INFLAMMATION IN AD PATIENTS - OBSERVATIONS 
AND IDEAS (PAPER I AND IV) 
SPMs are the key players in resolution of inflammation. To determine the resolution status in 
the AD brain, SPMs are of great importance to study. In Paper I and IV, we investigated the 
levels of SPMs in the postmortem brain of AD patients in comparison with age-matched 
controls. In Paper I, lower levels of LXA4 and MaR1 were found in the hippocampus of AD 
patients, whereas the levels of RvD1 did not show statistical differences compared to 
controls. In Paper IV, we further investigated a more complete profile of SPMs in the human 
entorhinal cortex, and found that the levels of RvD5, MaR1 and NPD1 were reduced in AD, 
whereas other SPMs were not. Rather, the collective levels of all RvEs were increased in the 
entorhinal cortex of AD patients. Together with data from a previous report [52], it seems that 
the levels of LXA4, MaR1 and NPD1 are decreased in the hippocampus, and that the levels of 
RvD5, MaR1 and NPD1 are decreased in the entorhinal cortex in AD patients, whereas the 
combined levels of E series resolvins are increased. These findings provide a characterization 
of the resolution pathway in the AD brain, but also provoke further questions, which could be 
partially answered in this thesis. 
5.1.1 Is there a resolution failure in the AD brain? 
Although SPMs are key players in resolution, measurements of SPMs could merely tell one 
side of the balance between inflammation and resolution. In Paper I, we have thus analysed 
the cytokine profile in the hippocampus of the same groups of AD patients and healthy 
controls. Among the 7 cytokines analysed, the levels of IL-1β, IL-6, IL-8, IL-12p70, IFN-γ 
and TNF-α, did not differ between AD and control group. However, the anti-inflammatory 
cytokine IL-10 was reduced in AD. As shown previously, the regulation of IL-10 expression 
is an important functional pathway to achieve resolution [206,207], and decreased levels of 
IL-10 may represent a net effect of the balance between inflammation and resolution. 
Moreover, although we could not confirm increased levels of pro-inflammatory cytokines, 
shown in some earlier reports, we did observe increased levels of HLA-DR in glial cells 
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(Figure 6), providing evidence of elevated pro-inflammatory actions other than cytokines. 
Furthermore, the hippocampal levels of peroxisome proliferator-activated receptor-γ (PPAR-
γ) were higher in AD patients. PPAR-γ has been shown to mediate LXA4-ALX/FPR2 
signalling, and activation of PPAR-γ increased LXA4 production in an experimental stroke 
model [176]. A similar mediator function of PPAR-γ was also found in NPD1 signalling 
[208].  Our findings of increased PPAR-γ levels in AD suggest a compensatory response to 
the reduced LXA4 production and insufficient pro-resolving signalling. 
Figure 6. Immunohistochemistry of HLA-DR staining in human hippocampus. (A) control 
brain; (B) AD brain; (C) clustered staining in a plaque of AD brain. Scale bar = 50 µm. 
5.1.2 Why is there a failure of resolution? 
Reduced SPMs can be the direct cause of resolution failure. While it was demonstrated that 
the relative percentage of AA and DHA in total FAs was reduced in AD [182], many other 
aspects need to be considered. For example, which cell types produce SPMs in the brain? In 
Paper I, we reported the existence of 15-LOX-2 in microglia and astrocytes. Unlike 15-
LOX-1 that catalyses the conversion of AA to both 15(S)-p-HETE and 12(S)-p-HETE, 15-
LOX-2 PPAR-γ catalyses the conversion of AA to 15(S)-p-HETE [209], indicating its 
involvement in LX synthesis [210,211]. Previous reports have shown that 15-LOX-1 and 5-
LOX are present in glia and neurons [212,213], and that COX-2 is only expressed by neurons 
[214]. Since AD is a neurodegenerative disease, could it be the cell loss that causes reduced 
SPMs? As shown by another study, loss of neurons in the AD brain seems not able to cause 
the severe loss of NPD1 [52]. And there is a significant gliosis in the AD brain [215], so loss 
of glia cells are also excluded for a reason of less SPMs. Is it caused by the famous star Aβ? 
We have recently shown that Aβ42 did not reduce the production of LXA4 and RvD1 from 
microglia [216]. The answer may lie somewhere else. 
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Surprisingly, all the protein levels of enzymes involved in SPM synthesis were found to be 
increased in the AD hippocampus ([212-214] and Paper I). While reduced levels of DHA in 
the AD brain [52] may be a possible explanation of lower derivatives RvDs, NPD1 and 
MaRs, the decrease in LXA4 remains unanswered. As shown in Paper I and IV, levels of the 
AA derivatives PGs, TxB2 and HETEs, were higher in the AD brain compared to controls. 
Thus, it seems that the AA cascade is producing less LXA4, but more of pro-inflammatory 
products. Indeed, AA metabolism is up-regulated in the AD brain, as shown by injection of 
radio-labelled AA in AD patients followed by PET imaging [217]. These findings suggest 
that a functional abnormality of SPM enzymes may be the cause for the reduction in LXA4 
and other SPMs. It is interesting to note that the enzyme 15-LOX-2 is decreased, or even not 
expressed, in cancer [218-220], a disease with uncontrolled cell growth, compared to AD 
with uncontrolled cell degeneration. Moreover, it has been shown that phosphorylation of 5-
LOX determines the production of 15-epi-LXA4 or LTB4 [221-223]. Thus, the exact role of 
LOXs in physiology and different diseases needs further research. 
Pro-resolving signalling depends also on the receptors for SPMs. ALX/FPR2 is the receptor 
for both LXA4 and RvD1 [123,131], as well as for Aβ [36,38-40]. In Paper I, we show that 
both neurons (CA2-4) and glia have staining for ALX/FPR2. The staining for ALX/FPR2 
was higher in glial cells in AD brains compared to controls, but there was no difference in 
neuronal staining. Since LXA4 is decreased and Aβ is increased in AD, it seems that there is 
an increase in detrimental Aβ-ALX/FPR2 signalling, and a decrease in beneficial LXA4-
ALX/FPR2 signalling, in glia and neurons of the AD brain. 
5.1.3 Is there any clinical relevance? 
Since postmortem examination is based on analysis of samples after death, a time point that 
usually represents the end stage of AD, it is difficult to tell how resolution markers are 
correlated to aetiology, clinical symptoms or pathological severity (all AD brains in Paper I 
and IV ranked Braak stage V-VI). However, it has been shown that in transgenic AD mice, 
LXA4 treatment improved cognition, reduced AD-like pathology, and rescued from synaptic 
loss, via suppressed inflammation and enhanced resolution [183,184]. Moreover, LXA4 and 
NPD1 provided pro-resolving effects and neuronal protection against Aβ toxicity in vitro 
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[52,208,224]. These studies provide substantial evidence that a lack of SPMs may be 
associated with less protection against AD, and may be a trigger or promoter for AD. 
In Paper I, we also analysed CSF samples from AD and MCI patients, as well as from SCI 
subjects, using EIA kits for LXA4 and RvD1. The levels of LXA4 were lower in AD patients 
compared to those in MCI and SCI subjects, and there was no difference between MCI and 
SCI subjects. The levels of RvD1 in CSF did not differ among the groups. These findings 
confirmed the resolution failure as shown in the brain. Notably, there was a positive 
correlation between the levels in CSF of these two SPMs and the MMSE scores. 
MCI and SCI are two special ‘control groups’. Mild cognitive impairment, MCI, is a term 
that defines a cognitive impairment that is worse than in normal aging, but not yet fulfils a 
diagnosis of dementia [225]. AD is the most common cause of MCI, or in other words, many 
MCI patients may convert to AD, in which case it is called MCI due to AD [225]. However, 
many other diseases, e.g. vascular dementia or Lewy body dementia, may also present as 
MCI at an early stage. Subjective cognitive impairment, SCI, is a term that is defined as self-
noticed cognitive impairment that is severe enough for the patient to see a doctor, but the self-
noticed impairment cannot be confirmed by the currently available cognitive tests, i.e. there is 
no objective proof of cognitive impairment [226]. However, this does not necessarily mean 
that the person has a completely healthy cognitive status. The symptoms may not be detected 
simply because of current methodological limits. Some of the cases with SCI may in fact be 
‘preclinical AD’, in which the cognitive symptoms are lacking, but the biomarkers are 
already altered [227]. It has been proposed that the conversion rate from SCI to MCI is 
around 6.7% per year [226]. Similarly to MCI, SCI is also a group of patients affected by 
different diseases, such as AD and depression [226].  
Despite the complexity of MCI and SCI, the levels of LXA4 in the CSF showed a cut-off 
between AD and MCI/SCI, suggesting a role of SPMs in the conversion to AD. Moreover, 
there was a trend of higher levels of LXA4 in SCI, suggesting that SCI is an even earlier stage 
of dementia than MCI. Whether decreased levels of SPMs in CSF samples can serve as early 
diagnostic markers needs further investigation. 
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5.1.4 Are SPMs always good? 
In Paper IV, we show that the levels of RvEs are elevated in the AD entorhinal cortex. 
Rather than simply explaining the phenomenon as a complementary effect to the reduction of 
other SPMs, a more challenging question could be placed: are SPMs always good? It was 
reported previously that RvE1 could promote the activation of mammalian target of 
rapamycin (mTOR) and ribosomal protein S6 kinase (p70S6K) [228], which are key players 
in tau phosphorylation [229]. Thus, the elevated RvEs could be suspected to have a role in tau 
pathology in AD. More research is needed to give an answer, such as whether RvE1 
specifically activates the mTOR complex 1 (mTORC1)/p70s6K pathway, that is responsible 
for tau phosphorylation, or whether it activates both mTORC1 and 2, of which the latter is 
supposed to be a cell survival promoter [230]. 
5.2 RESOLUTION OF INFLAMMATION IN AGING - REASONING (PAPER II 
AND III) 
As indicated earlier in the thesis, aging is the greatest risk factor for developing AD [57]. 
Following our studies to characterize the status of resolution in AD patients, we then tried to 
explore how resolution is modulated in successful aging and abnormal aging. 
5.2.1 What can be learned from successful aging? 
In Paper II, we found an increase in MHC-II, a marker for activated microglia, with age in 
the mouse model of successful aging, SAMR1 mice. This is in line with the 
immunosenescence theory, that the macrophages become senescent with age, and 
increasingly display a more pro-inflammatory phenotype [65]. As aging is a chronic progress 
with increased inflammation even in healthy conditions [65,66], it is important to notice the 
other end of the scale, the resolution of inflammation. In the SAMR1 mice, the LXA4 and 
RvD1 levels were not increased or decreased with age, but their receptor, ALX/FPR2 was 
elevated with age. Thus, the pro-resolving signalling seemed to be enhanced through the 
receptor. Increased levels of ALX/FPR2 have been observed also after acute inflammatory 
conditions. For example, ALX/FPR2 expression was induced in horse tendons after acute 
injury, or after stimulation with IL-1β or PGE2, suggesting an endogenous program to resolve 
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inflammation [231]. However, a chronic increase in ALX/FPR2 may bring risks. As it is 
known that Aβ is also using ALX/FPR2 as a receptor to transduce pro-inflammatory signals 
[38-40], the increase in ALX/FPR2 levels with age is potentially creating an increased risk of 
Aβ-dependent toxicity in the brain. Importantly, this finding also indicated that aging and 
inflammation, rather than Aβ [216], may be the promoter for ALX/FPR2 expression. 
Moreover, chemerin, a chemoattractant molecule increased in multiple sclerosis [232], had a 
tendency towards reduction with age in the hippocampus of SAMR1 mice, indicating an 
attempt to lower the pro-inflammatory factors in a successful aging process. 
To conclude, successful aging is achieved by balancing the inflammation and resolution, as 
shown in the SAMR1 model in Paper II. This idea agrees with the previous finding in 
humans, that healthy centenarians always present equal elevations of inflammatory and anti-
inflammatory markers [67,68].  
5.2.2 The unbalanced scale in abnormal aging 
As we can learn from the SAMR1 mice and human centenarians, a balance between 
inflammation and resolution is essential to achieve successful aging. We did not observe a 
change in SPM levels in the old SAMP8 mice, neither with age nor compared to SAMR1 
mice, but an excessive increase in inflammatory markers was obvious in the SAMP8 mice, as 
shown by previous studies [233,234]. Levels of MHC-II measured by western blot, and 
immunoreactivity of F4/80 shown by immunohistochemistry, were dramatically higher in the 
9-month old SAMP8 mice, compared to 9-month old SAMR1 or 2-month old SAMP8 mice. 
In line with this, chemerin was increased with age in SAMP8 mice, compared to the trend of 
decrease in SAMR1 mice. We thus conclude that there was an elevated inflammation in the 
abnormal aging of SAMP8 mice, and that this increase was excessive in comparison with the 
normal aging in SAMR1 mice. On the other hand, resolution of inflammation in abnormal 
aging of SAMP8 mice remained at a similar level as that seen upon the normal aging of 
SAMR1 mice, as shown by equal levels of SPMs, as well as their receptor ALX/FPR2, in the 
two strains. Thus, excessive inflammation and insufficient resolution presented a disturbed 
balance in the SAMP8 mice. 
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5.2.3 From animal model to human translation 
In Paper III, we analysed SPM release from PBMCs obtained from AD patients given 
placebo. After the 6 months placebo supplement, there was a drop in LXA4 and RvD1 levels 
released from the PBMCs. Although a period of 6 months is quite short compared to the 
whole aging process, it is relatively long when compared to the 4 - 8 years survival time after 
a diagnosis of AD [57]. Thus, the reduction in LXA4 and RvD1 release from PBMCs 
suggested a decreased ability of the body to produce SPMs with age in AD patients, 
providing partial support for the findings of decreased SPMs in Paper I and IV. The 
decreased secretion of SPMs upon age in humans (Paper III), and unchanged levels with age 
in the SAMP8 mice (Paper II) with aging may be simply reflecting the discrepancy between 
a human disease and an animal model. For example, it is well known that transgenic mice 
with mutant familial AD genes only present Aβ pathology, but rarely with tau pathology or 
neuronal loss [195]. However, it is also important to note that Paper III is an investigation of 
peripheral immune cells ex vivo, and whether the reduction seen in PBMCs reflects the 
change in the brain is unknown. Thus, whether decreased levels of SPMs in the AD brain and 
CSF represent early events or not, needs further investigation, but the SAMP8 and SAMR1 
mice could still stand for good models to study the mechanism of balance between 
inflammation and resolution in abnormal and successful aging, respectively. 
In the SAMP8 mice, we observed Aβ deposits in the hippocampus at 9 months, and this was 
accompanied by elevated p-tau levels compared to those at 2 months age. The simultaneous 
presence of AD-like pathologies and excessive inflammation in SAMP8 mice supports the 
relation between AD and inflammation. Interestingly, in the hippocampus of 9 months old 
SAMP8 mice, leukocyte type 12-LOX (L12-LOX, analogue of human 15-LOX-1) showed 
clustered immunostaining that was colocalized with Aβ deposits. Furthermore, there was a 
positive correlation between the levels of L12-LOX and p-tau levels in SAMP8, but not 
SAMR1 mice. Other studies showed that overexpression of L12-LOX increases the levels of 
Aβ [235], which may be produced at synapses [236]. Thus, the colocalization of L12-LOX 
and Aβ suggests a potential novel role of LOXs in the Aβ cascade, e.g. β- or γ-secretase 
activities. The correlation between L12-LOX and p-tau is in line with the previous report 
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showing that overexpression of L12-LOX increases p-tau levels in AβPP transgenic mice 
[237].  
Overall, it seems that L12-LOX is a ‘bad guy’. Indeed, L12-LOX levels are increased in the 
AD brain [212]. However, there was no change with age in the SAMP8 mice, and there was 
even a decrease in L12-LOX levels compared to SAMR1 mice at 9 months. In contrast, L12-
LOX levels were elevated with age in SAMR1 mice, the normal aging model. These 
observations raise questions regarding our theory, and to find an answer, we need to take a 
systematic overview. In the SAMR1 mice, while L12-LOX levels were increased with age, 
the levels of 5-LOX were decreased. Such a counter-regulation of L12-LOX and 5-LOX was 
proposed as an ‘anti-inflammatory’ activity in a previous report [238]. This active regulation 
of LOXs was not seen in the hippocampus of SAMP8 mice, in which both LOXs remained 
unchanged with age. Furthermore, the correlation between L12-LOX and p-tau was only 
observed in the SAMP8 strain, suggesting a functional alteration of this enzyme in this strain. 
These observations make further demands for research on the functional roles of LOXs in 
AD, as already discussed in Section 5.1.2. 
5.3 EFFECTS OF N-3 PUFA SUPPLEMENTATION ON SPMS - PRACTICE 
(PAPER III) 
SPMs are derivatives from PUFAs, especially the n-3 FAs DHA and EPA. The hypothesis of 
Paper III was that supplementation with DHA and EPA may result in an increase of their 
derivative SPMs. The study was based on a clinical trial, the OmegAD study (registered at 
clinicaltrials.gov as NCT00211159). It was a randomized, double-blind and placebo-
controlled trial concluded by 174 AD patients. The primary outcome of the OmegAD study 
was that the cognitive decline did not differ between the n-3 FA- and placebo-supplemented 
group [112]. However, when analysing a sub-group of patients with MMSE > 27 prior to the 
trial, the cognitive decline was prevented by n-3 FA supplementation [112].  
We obtained PBMCs from 15 patients, of whom 8 patients were supplemented with n-3 FAs, 
and 7 patients with placebo. Most of these 15 patients had relatively high MMSE scores 
before the trial, and hence the cognitive changes of these patients were in line with the 
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finding that cognitive decline was prevented by n-3 FA supplementation. The PBMCs were 
cultured ex vivo and exposed to 7 µM Aβ40 peptide. Analysis of the PBMC culture medium, 
showed that levels of LXA4 and RvD1 were reduced after 6 months placebo supplementation, 
and there was no change in the n-3 FA supplemented group. Collectively, the trend of 
changes in SPMs is in parallel with cognitive function, indicating a potential association. 
However, unlike the correlation between SPM levels and MMSE scores found in the CSF, 
statistical analysis did not show a correlation between the changes of SPM levels released 
from PBMCs, and the MMSE scores. Nevertheless, changes in SPMs were correlated to 
changes in the transthyretin (TTR) levels in plasma. TTR is a 55 kDa homotetramer, acting as 
a protein carrier in blood and CSF. It has been shown that TTR is present in senile plaques 
[239], and may play a beneficial role in AD through inhibition of Aβ toxicity [240-244]. 
Thus, the correlation between SPMs and TTR warranted further investigation regarding the 
relationship between SPMs and TTR.  
Returning to the original hypothesis, supplementation with DHA and EPA may result in 
increased production of SPMs. The DHA and EPA levels were dramatically elevated in the 
plasma after 6 months of n-3 FA supplementation, and there was a small decrease in AA. 
These PUFAs were not changed in the placebo group. However, there was no change in the 
levels of RvD1 or LXA4 after the n-3 supplementation. However, in the placebo group, there 
was a reduction in these SPMs, even though the PUFA levels in plasma were unchanged after 
the trial.  
Indeed, supplementation with n-3 FAs has been shown to increase levels of NPD1, RvD1 and 
RvE1, in visceral adipose tissue of patients with severe obesity [245]. In healthy people, n-3 
FA supplementation increased the plasma levels of RvE1, but not other SPMs [246]. Despite 
the different doses and duration of the supplementation, these complex results indicate that 
supplementation with n-3 FAs may not be sufficient to increase the SPM levels. This could 
be due to an altered incorporation of n-3 FAs into different tissues or a disturbed PUFA 
metabolism (e.g. abnormal functions of LOXs), especially under certain diseases, such as 
AD. For a sufficient supplementation with n-3 FAs to exert treatment effects, there are many 
questions placed beyond. For example, DHA transportation from the periphery to the brain 
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was reduced in ApoE4 transgenic mice [247]. It has not been clear until recently that DHA is 
transported across the blood brain barrier into the brain by Mfsd2a, a member of the major 
facilitator superfamily [248,249]. Whether Mfsd2a is altered in AD or in a person at risk to 
develop the disease, is unknown. Moreover, supplementation with n-3 FAs increases 
oxidative stress and shortens the lifespan of SAMP8 mice [250]. This further emphasizes the 
question whether PUFAs are metabolized into beneficial products in a proper way, and 
whether SPM enzymes are functioning correctly in certain populations with an abnormal 
aging process. 
In summary, the efficacy of n-3 FA supplementation in AD patients is still far from a clear 
conclusion. A novel strategy based on SPMs instead of their precursors is appealing, from the 
perspective of a more direct intervention. For example, in a model for ischemic stroke, 
administration of NPD1 reduced total brain infarct volume by 87%, compared to DHA, 75% 
[174].  
5.4 FUNCTIONAL ROLES OF SPMS IN THE BRAIN - LOOKING FORWARD 
(PAPER IV) 
In order to provide more evidence regarding the potential SPM treatment effects in AD, we 
treated human neuronal cells and microglia with SPMs combined with different conditions in 
Paper IV. 
5.4.1 Effects of SPMs on neurons - More than anti-inflammation 
As described in Paper I and II, hippocampal neurons express ALX/FPR2, indicating a 
potential direct action of LXA4 and RvD1 on neurons. In Paper IV, differentiated 
neuroblastoma cells were treated with SPMs (LXA4, RvD1, NPD1 and MaR1) in the 
presence or absence of staurosporine. The SPMs did not only protect the neurons from 
staurosporine-induced apoptosis, but also enhanced cell survival at basal conditions. 
Staurosporine is a protein kinase inhibitor that is used in neurodegenerative models to induce 
apoptosis [251-253], probably via increasing oxidative stress [203]. The protective effects of 
SPMs against staurosporine are in line with previous reports on NPD1-induced 
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neuroprotection [254]. Despite the fact that the effects of SPMs in Study IV were obtained in 
vitro, it is of interest to note a neurotrophic effect of SPMs under basal conditions. 
The direct effects of SPMs on neurons suggest that resolution, or pro-resolving mediators, 
may have other functions than to counteract/end inflammation. Besides to stop excessive and 
detrimental inflammatory signals, SPMs may also have follow-up effects by restoring 
homeostasis of the inflamed tissue, as evidenced previously by the long-term repair effects of 
DHA and NPD1 in a stroke model [174]. These results further support the idea that resolution 
is more than anti-inflammation [118]. 
5.4.2 Effects of SPMs on microglia - A focus on MaR1 
A feature of pro-resolving activities is to enhance phagocytosis. We treated the human 
microglial cell line, CHME3, with four types of SPMs (LXA4, RvD1, NPD1 and MaR1) in 
the presence of Aβ42 peptide. The microglial phagocytosis of Aβ42 peptide was increased by 
MaR1, but not by LXA4, RvD1 or NPD1, all of which have been reported previously to 
increase phagocytosis in other cellular models [255,256]. Notably, LXA4 and NPD1 were 
shown to enhance the phagocytosis of zymosan and latex beads by mouse macrophages in 
vitro [255], and RvD1 promoted phagocytosis of fibrillar Aβ42 by human macrophages, 
differentiated from PBMCs ex vivo [256]. The use of different cellular models and different 
targets for phagocytosis, may explain the discrepancy between our study and others. In 
continued studies on the CHME3 microglia, we focused on the effects of MaR1 on their 
phenotype. Under naïve conditions, MaR1 decreased the expression of the microglial surface 
marker CD33. CD33 expression was increased in the brain of AD patients, and inhibition of 
CD33 was found to increase Aβ clearance [257]. Thus, the enhanced Aβ42 uptake in CHME3 
microglia may be mediated by reducing the CD33 expression. Furthermore, MaR1 reduced 
the pro-inflammatory markers CD80, CD86, CD11b and MHC-II, suggesting a suppression 
of M1 phenotype in CHME3 cells. However, the M2 anti-inflammatory markers CD163 and 
CD206 were not increased by MaR1 treatment, in contrast to a previous report on 
macrophages [143]. This discrepancy could be explained by the fact that CHME3 microglia 
express a high pro-inflammatory profile at basal condition [197], and thus MaR1 could only 
dampen the pro-inflammatory polarization, but not significantly enhance the anti-
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inflammatory phenotype. The high pro-inflammatory polarization at basal conditions, and 
potential other genetic deficits, of the CHME3 cells may also be a reason for the lack of pro-
phagocytic effects of LXA4, RvD1 and NPD1. 
Maresins are the most recently discovered SPMs, and further investigation is needed to 
characterize their roles in inflammation and disease. The evidence of reduced levels of MaR1 
in AD brains, and the pro-resolving functions against Aβ and inflammation in vitro 
demonstrated by our studies provide fundamental new knowledge for further exploration of 
the role of MaR1 in AD.  
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6 CONCLUDING REMARKS AND FUTURE PERSPECTIVES 
6.1 CONCLUDING REMARKS 
The main aim of this thesis was to provide an overview of resolution of inflammation in AD. 
The results of our studies demonstrated a disturbed resolution pathway in AD patients, by 
analysis of brain and CSF samples, and functional cellular studies ex vivo. The thesis also 
describes basic characterization of the resolution pathway in the central nervous system, 
including the levels of SPMs, the distribution of SPM enzymes and receptors, and the levels 
of downstream effectors of SPMs. Moreover, mouse models of normal and abnormal aging 
were compared in the context of resolution. Finally, functions of four major SPMs on brain 
cells were analysed. The key findings can be concluded as: 
⎯ Levels of LXA4, RvD5, NPD1 and MaR1 were reduced in the AD brain. LXA4 levels 
were reduced in CSF samples of AD patients, and the CSF levels of LXA4 and RvD1 
were correlated with cognitive function.  
⎯ Distribution of SPM enzymes and receptors in the human brain were characterized, 
and an alteration of these factors were found in the AD brain.  
⎯ The release of SPMs from PBMCs of AD patients was reduced in a short aging period 
of 6 months, and the reduction was prevented by n-3 FA supplementation. 
⎯ Abnormal aging in mice was associated with insufficient pro-resolving signals, and 
altered resolution pathway factors were associated with AD-like pathologies. 
⎯ SPMs provided neuronal protection under basal and stimulated conditions. MaR1 
enhanced microglial phagocytosis of Aβ42, and reduced  microglial expression of pro-
inflammatory markers. 
6.2 FUTURE PERSPECTIVES 
The discovery of SPMs is recent, and, probably, new SPMs will be found. Clearly, SPMs and 
the resolution of inflammation have emerging implications in many diseases including AD. 
However, there are many questions beyond establishing the full picture of SPMs and 
resolution in AD, such as:   
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⎯ Is the deficit of resolution in AD a consequence, or a reason? We found a decreased 
ability to produce SPMs with age in AD patients, and there was a drop in CSF levels 
of SPMs between MCI/SCI and AD. It is still not clear how and why these changes 
occurr, and whether leading or consequential. 
⎯ How do SPMs and resolution interact with the pathophysiology of AD? For example, 
since both LXA4 and Aβ bind to ALX/FPR2, it will be of interest to establish whether 
the binding is competitive or not, and what is the consequential signalling on different 
cell types, e.g. neurons and glia. 
⎯ What is the specific role of each SPM? So far, most of the conclusions regarding 
SPMs have been collective from many different experimental settings that test one or 
two SPMs, and studies comparing the functions of SPMs are few, so far. 
⎯ Are SPMs always good? Based on current knowledge, SPMs have been proposed as 
beneficial, which may be true. However, because of their novelty, further research is 
necessary to confirm the safety. The RvE1-based drug RX-10001 has completed a 
Phase I trial, and RX-10045 has completed a Phase II  trial on dry eye syndrom 
(registered at clinicaltrials.gov as NCT00941018 and NCT00799552, respectively). 
Concivably, these first SPM drugs will provide answers to some of the questions. 
To picture the future much further ahead, despite the fact that it has not yet been clarified 
whether the disturbance of resolution is an aetiological cause, or a consequence of AD, SPMs 
represent a novel therapeutic strategy in AD, as well as many other inflammation-related 
diseases. Anti-inflammatory drugs did not favour the production of SPMs, but were rather 
‘resolution toxic’ [146], indicating an additional reason for the failure of NSAIDs in clinical 
trials. PUFAs may have their own biological significance, and supplementation with PUFAs 
for human health overwhelmed the industry and research, as well as society. However, this 
should not hamper an investigation of novel and specific SPMs for the treatment in certain 
diseases associated with a disturbed resolution, such as AD. 
Citing the words by Professor Bengt Samuelsson when talking about PGs, the future 
perspectives of SPMs and resolution of inflammation may be expected in a similar way: “It's 
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a control system for the cells that participates in many biological functions. There are endless 
possibilities of manipulating this system in drug development.” 
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